Ironwood issues FY 2026 guidance; LINZESS net sales targeted at $1.125-1.175B

IRONWOOD PHARMACEUTICALS INC

FY 2026 LINZESS U.S. net sales guided at $1.125B-$1.175B; total revenue $450M-$475M.
FY 2026 adjusted EBITDA expected >$300M; FY 2025 guidance maintained at >$135M.
Ended Q4 2025 with >$200M cash; LINZESS list price reduced effective Jan 1, 2026.
FDA aligned on confirmatory Phase 3 trial design for apraglutide (SBS-IF); trial to start H1 2026.
Strategic alternatives review ongoing to maximize shareholder value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.